People: ARYx Therapeutics Inc (ARYX.PK)

ARYX.PK on OTC Markets Group

0.00USD
2:39pm EDT
Price Change (% chg)

$0.00 (-2.44%)
Prev Close
$0.00
Open
$0.00
Day's High
$0.00
Day's Low
$0.00
Volume
13,000
Avg. Vol
29,495
52-wk High
$0.07
52-wk Low
$0.00

Search Stocks

Summary

Name Age Since Current Position

Paul Goddard

 62 2005 Chairman of the Board, Chief Executive Officer

John Varian

 52 2011 Chief Operating Officer

David Nagler

 57 2003 Vice President - Corporate Affairs, Secretary

Nicholas Simon

 57 2002 Director
» Insider Trading

Biographies

Name Description

Paul Goddard

 Dr. Paul Goddard, Ph.D. has served as the Chairman of Board of ARYx Therapeutics, Inc. since August 2003 and was appointed Chief Executive Officer in April 2005. From March 2000 to August 2005, Dr. Goddard served as chairman and part-time executive of several companies including A.P. Pharma, Inc. and XenoPort, Inc., a biopharmaceutical company. From October 1998 until March 2000, he was chief executive officer of Elan Pharmaceuticals, Inc., division of Elan Corporation plc, a biotechnology company. He was chief executive officer of Neurex Corporation, a biotechnology company, from February 1991 until October 1998 when the company was acquired by Elan Corporation plc. Prior to 1991, Dr. Goddard held senior management positions at SmithKline Beecham plc, a pharmaceutical company, including senior vice president strategic marketing and senior vice president Far East region. He obtained his doctorate degree from St. Mary's Hospital, London, in the area of etiology and pathophysiology of colon cancer. Dr. Goddard serves on the board of directors of Adolor Corporation, a biopharmaceutical company, as chairman of A.P. Pharma, Inc., a pharmaceutical company, and as lead director of Onyx Pharmaceuticals, Inc., a biopharmaceutical company.

John Varian

 Mr. John Varian is Chief Operating Officer of Aryx Therapeutics Inc. He served as Chief Financial Officer of the Company. He has served as Chief Operating Officer since December 2003 and as Chief Financial Officer since April 2006. He was formerly chief financial officer of Genset S.A., a biotechnology company. He also participated as a key member of the negotiating team in the sale of the company to Serono of Switzerland. From October 1998 to April 2000, Mr. Varian served as senior vice president, finance and administration of Elan Pharmaceuticals, Inc. He was chief financial officer of Neurex Corporation from June 1997 until October 1998 when the company was acquired by Elan Corporation plc. Mr. Varian is a founding member of the Bay Area Bioscience Center and a former chairman of the Association of Bioscience Financial Officers International Conference. Mr. Varian received a B.B.A. degree from Western Michigan University.

David Nagler

 Mr. David Nagler is Vice President - Corporate Affairs, Secretary of ARYx Therapeutics, Inc. He has served as Vice President, Corporate Affairs, and Secretary since July 2003. From June 1995 to September 2002, Mr. Nagler served at Genentech, Inc., a biotechnology company, including as its vice president of human resources and its senior director of government affairs. Prior to joining Genentech, Mr. Nagler co-founded JLA Associates in Sacramento, a legislative consulting and association management company that he later sold to Nossaman Guthner Knox & Elliott LLP, a law firm. Mr. Nagler received a bachelor of arts degree in public policy and philosophy from the University of California, Berkeley. Mr. Nagler is a member of the board of directors of UC Davis CONNECT, a program designed to foster the success of new business ventures in the Sacramento region. Mr. Nagler also serves in the City of Pleasanton, California as an appointed member of the City Human Services Commission.

Nicholas Simon

 Mr. Nicholas J. Simon is Director of ARYx Therapeutics, Inc. Mr. Simon has served as a Managing Director of Clarus Ventures, a venture capital firm focused on life sciences companies, since the firm's inception in February 2005. In addition, Mr. Simon has been a general partner of MPM BioVentures III, a healthcare venture capital fund, since October 2001. From April 2000 to July 2001, Mr. Simon was chief executive officer and founder of Collabra Pharma, Inc., a pharmaceutical company. Mr. Simon served in various management positions at Genentech, Inc., including as its vice president of business and corporate development. Mr. Simon is currently on the board of directors of several pharmaceutical companies: Achillion, Inc., Avanir, Inc., Neosil, Inc., QuatRx Pharmaceuticals Company, Pearl Therapeutics, Inc., Poniard Pharmaceuticals, Inc., Sientra, Inc. and Verus Pharmaceuticals, Inc. He is also on the advisory council of the Gladstone Institute, a private not-for-profit research institute affiliated with the University of California, San Francisco. Mr. Simon received a bachelor of sciences degree in microbiology from the University of Maryland and a masters in business administration in marketing from Loyola College.

Basic Compensation

Name Fiscal Year Total

Paul Goddard

 865,285

John Varian

 538,333

David Nagler

 392,663

Nicholas Simon

 --
As Of 30 Dec 2009

Options Compensation

Name Options Value

Paul Goddard

 54,166 115,000

John Varian

 0 0

David Nagler

 0 0

Nicholas Simon

 0 0

Insider Trading

» Full list on Insider Trading
Search Stocks